TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide present in virtually all human and animal cells. It is the most abundant member of the beta-thymosin family and plays a critical role in tissue repair, cell migration, blood vessel formation, and wound healing. TB-500 promotes angiogenesis, cell differentiation, and anti-inflammatory responses. It has been extensively studied for its regenerative properties in cardiac tissue, skin, corneal, and musculoskeletal healing applications.
14-21 days (long-acting)
Subcutaneous injection
2
4963 Da
TB-500 works primarily through its interaction with actin, where it promotes cell migration and proliferation. Key mechanisms include: (1) Sequestration of G-actin, regulating actin polymerization and cell motility; (2) Upregulation of angiogenesis and blood vessel formation; (3) Promotion of cell migration via the LIM domain kinase (LIMK) pathway; (4) Anti-inflammatory effects through modulation of cytokine expression; (5) Cardioprotective effects including reduction of infarct size and promotion of cardiac repair; (6) Promotion of stem cell differentiation and tissue regeneration. TB-500 also interacts with Ku80 in the nucleus, influencing gene expression related to tissue repair.
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino acid peptide involved in cell migration, wound healing, and tissue repair. Evidence comes primarily from in vitro studies and animal models demonstrating accelerated wound healing, reduced inflammation, and tissue regeneration. No human clinical trials have been completed. TB-500 is widely used in veterinary medicine, particularly for equine injuries, but human use remains off-label and experimental.
Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES